Clinical Trial Update: Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating N-acetylcysteine for Selenoprotein N-related Myopathy (SEPN1-RM) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Selenoprotein N-related Myopathy

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Selenoprotein N-related Myopathy | Phase 2, Phase 3 | Status: TERMINATED